| 1 | resulting | 9,279 |
| 2 | culminating | 71 |
| 3 | hyper-connectivity | 3 |
| 4 | lexicalized | 3 |
| 5 | ω-diols | 3 |
| 6 | 'published | 2 |
| 7 | 0.10±0.01 | 2 |
| 8 | 33/30 | 2 |
| 9 | 399gln | 2 |
| 10 | absent/present/abundant | 2 |
| 11 | aphtha | 2 |
| 12 | apkcs | 2 |
| 13 | detaches | 2 |
| 14 | enamels | 2 |
| 15 | eventuating | 2 |
| 16 | garnishes | 2 |
| 17 | gse14407 | 2 |
| 18 | half-submerged | 2 |
| 19 | harris-shorr | 2 |
| 20 | macrodiscectomy | 2 |
| 21 | n'-disubstituted | 2 |
| 22 | o-bidentate | 2 |
| 23 | pneumonia/ardss | 2 |
| 24 | redisplacement/nonunion | 2 |
| 25 | rs3828610 | 2 |
| 26 | src-3/amplified | 2 |
| 27 | 'decline | 1 |
| 28 | 'probiotics | 1 |
| 29 | 'pumped | 1 |
| 30 | 'scenarios | 1 |
| 31 | +13/+17 | 1 |
| 32 | -5.9±6.5 | 1 |
| 33 | -8.1±6.4 | 1 |
| 34 | -patient | 1 |
| 35 | 0.04+/-3.94 | 1 |
| 36 | 0.23±0.04 | 1 |
| 37 | 0.28±0.01 | 1 |
| 38 | 0.4985 | 1 |
| 39 | 0.49±0.04 | 1 |
| 40 | 0.52±0.03 | 1 |
| 41 | 0.63/0.37 | 1 |
| 42 | 0.696+/-0.1 | 1 |
| 43 | 0.7406 | 1 |
| 44 | 0.745+/-0.03 | 1 |
| 45 | 0.82-fold | 1 |
| 46 | 0.83+/-3.88 | 1 |
| 47 | 0.86±0.51 | 1 |
| 48 | 0.87-0.87 | 1 |
| 49 | 09/gz/1081 | 1 |
| 50 | 1-15cm2 | 1 |
| 51 | 1.00-1.68 | 1 |
| 52 | 1.00/0.00 | 1 |
| 53 | 1.2-dicloroethane | 1 |
| 54 | 1.29-2.74 | 1 |
| 55 | 1.3db | 1 |
| 56 | 1.4-11.5 | 1 |
| 57 | 1.52-3.95 | 1 |
| 58 | 1.54-3.27 | 1 |
| 59 | 1.59+/-4.57 | 1 |
| 60 | 1.7±0.52 | 1 |
| 61 | 1.93±1.03 | 1 |
| 62 | 101.3±27.1 | 1 |
| 63 | 11,855 | 1 |
| 64 | 11cen-p14 | 1 |
| 65 | 12.57±2.05mg/dl | 1 |
| 66 | 12.7±7.9 | 1 |
| 67 | 12.7±9.5 | 1 |
| 68 | 134/qaly | 1 |
| 69 | 15.97±1.96mg/dl | 1 |
| 70 | 16±6°c | 1 |
| 71 | 18.0-30.4 | 1 |
| 72 | 182,546 | 1 |
| 73 | 2,777 | 1 |
| 74 | 2-dechloroethylifosfamide | 1 |
| 75 | 2-hydroxyisobutyrate | 1 |
| 76 | 2.18+/-0.76 | 1 |
| 77 | 2.4+/-0.3 | 1 |
| 78 | 2.9+/-1.3 | 1 |
| 79 | 20,290 | 1 |
| 80 | 20alpha-dihydroxypregn-4-en-3-one | 1 |
| 81 | 268/1075 | 1 |
| 82 | 283/1072 | 1 |
| 83 | 3.1+/-1.6 | 1 |
| 84 | 31-60° | 1 |
| 85 | 32,110 | 1 |
| 86 | 4,4'-bipyridine-bridged | 1 |
| 87 | 4.1±1.2mm | 1 |
| 88 | 4.59±2.02 | 1 |
| 89 | 4.854 | 1 |
| 90 | 43.2mg | 1 |
| 91 | 4‒5 | 1 |
| 92 | 5.3±8.3weeks | 1 |
| 93 | 50.6-79.6 | 1 |
| 94 | 57°w | 1 |
| 95 | 61-90° | 1 |
| 96 | 64.4±27.5 | 1 |
| 97 | 7.1±13.9 | 1 |
| 98 | 7.98±0.41 | 1 |
| 99 | 77/111 | 1 |
| 100 | 7963 | 1 |
| 101 | 8-diones | 1 |
| 102 | 8-hydroxyclomipramine | 1 |
| 103 | 803a/a | 1 |
| 104 | 9.3/10 | 1 |
| 105 | 9890 | 1 |
| 106 | abstracts/papers | 1 |
| 107 | alkynyltrifluoroborate | 1 |
| 108 | amman-jordan | 1 |
| 109 | analysis.evidence | 1 |
| 110 | ancylostomideos | 1 |
| 111 | anemia/hemorrhage | 1 |
| 112 | angled-tip | 1 |
| 113 | antagonists-is | 1 |
| 114 | anti-c5 | 1 |
| 115 | anti-ca-present | 1 |
| 116 | anti-ro52 | 1 |
| 117 | antibiotics/steroids/antihistamines | 1 |
| 118 | aq-27 | 1 |
| 119 | arg41 | 1 |
| 120 | asp863 | 1 |
| 121 | azospermia | 1 |
| 122 | bafetinib | 1 |
| 123 | basophilia | 1 |
| 124 | belingai | 1 |
| 125 | biphenols | 1 |
| 126 | bsrt | 1 |
| 127 | c.279-280insat | 1 |
| 128 | c262y/wt | 1 |
| 129 | c282y/c282y | 1 |
| 130 | c7/th1 | 1 |
| 131 | ca/p-containing | 1 |
| 132 | cardiomagnyl | 1 |
| 133 | cassrs | 1 |
| 134 | cdxzn1-xse-cdyzn1-ys | 1 |
| 135 | cephalothorax | 1 |
| 136 | ci:0.95-2.43 | 1 |
| 137 | ci:0.99-2.51 | 1 |
| 138 | cns-lupus | 1 |
| 139 | co-organized | 1 |
| 140 | coiled-coils | 1 |
| 141 | core-ceramic/veneer | 1 |
| 142 | cowork | 1 |
| 143 | cpd-photolyase | 1 |
| 144 | cross-contaminations | 1 |
| 145 | crystallising | 1 |
| 146 | custom-manufactured | 1 |
| 147 | cutting-in | 1 |
| 148 | decentre | 1 |
| 149 | dederivation | 1 |
| 150 | desisting | 1 |
| 151 | digitalis-especially | 1 |
| 152 | dimission | 1 |
| 153 | disbalances | 1 |
| 154 | disulphides | 1 |
| 155 | dppc/pg | 1 |
| 156 | drb1*09012 | 1 |
| 157 | driving/riding | 1 |
| 158 | e-prints | 1 |
| 159 | edads | 1 |
| 160 | egerton | 1 |
| 161 | end-labeled | 1 |
| 162 | endo-1,4-β-mannanases | 1 |
| 163 | endo-1→3-β-d-glucanase | 1 |
| 164 | epilepsy/seizures | 1 |
| 165 | erinia | 1 |
| 166 | eskornade | 1 |
| 167 | esspecially | 1 |
| 168 | estrangement | 1 |
| 169 | f-e2 | 1 |
| 170 | f.c-e2 | 1 |
| 171 | feloten | 1 |
| 172 | ffar2 | 1 |
| 173 | folloed | 1 |
| 174 | framing-changing | 1 |
| 175 | g3pdhs | 1 |
| 176 | gender-sensitised | 1 |
| 177 | genno-shoko | 1 |
| 178 | h63d/h63d | 1 |
| 179 | heii-san | 1 |
| 180 | hexanedinitrile | 1 |
| 181 | hollow-structured | 1 |
| 182 | homovanillic-acid | 1 |
| 183 | hpa-3a | 1 |
| 184 | hsp84-transgene | 1 |
| 185 | hwangryun-hae-dok-decotion | 1 |
| 186 | hyper-proportional | 1 |
| 187 | ido1-overexpression | 1 |
| 188 | ii-article | 1 |
| 189 | illegally-engaged | 1 |
| 190 | imipramin | 1 |
| 191 | immune-isolated | 1 |
| 192 | ischémiques | 1 |
| 193 | ita-oba | 1 |
| 194 | jugal | 1 |
| 195 | kaitha | 1 |
| 196 | khorasan-1037 | 1 |
| 197 | laminin-2 | 1 |
| 198 | landmarked | 1 |
| 199 | lazanda® | 1 |
| 200 | ld3 | 1 |
| 201 | leukoerythroblastosis | 1 |
| 202 | lignosulfonates | 1 |
| 203 | lipocrits | 1 |
| 204 | lipomeningocele | 1 |
| 205 | liqpiritin | 1 |
| 206 | log-uacr | 1 |
| 207 | m3a | 1 |
| 208 | m3b | 1 |
| 209 | megusurino-ki | 1 |
| 210 | metallothione- | 1 |
| 211 | metxl50 | 1 |
| 212 | mg/al | 1 |
| 213 | miii | 1 |
| 214 | multicenter-trials | 1 |
| 215 | nival | 1 |
| 216 | notch1-4 | 1 |
| 217 | npnz | 1 |
| 218 | o-didesmethylvenlafaxine | 1 |
| 219 | obstruction/clogging | 1 |
| 220 | oprf/opri | 1 |
| 221 | orchid-epididymitis | 1 |
| 222 | p.l647f | 1 |
| 223 | painrelieving | 1 |
| 224 | particpation | 1 |
| 225 | pateint | 1 |
| 226 | pcrrflp | 1 |
| 227 | pdmpcisolated | 1 |
| 228 | peptidoleukotrienes | 1 |
| 229 | pg+cq | 1 |
| 230 | phloretin-3',5'-di-c-glucoside | 1 |
| 231 | pn1mi+ | 1 |
| 232 | pneuomothorax | 1 |
| 233 | polysaccharopeptide | 1 |
| 234 | polyuria/dehydration | 1 |
| 235 | preincubational | 1 |
| 236 | primases | 1 |
| 237 | progresssion | 1 |
| 238 | prostato-rectal | 1 |
| 239 | q-max | 1 |
| 240 | r=-0.032 | 1 |
| 241 | r=.87 | 1 |
| 242 | r=0.155 | 1 |
| 243 | rechu-to | 1 |
| 244 | regin | 1 |
| 245 | remobilisation | 1 |
| 246 | rfs/os | 1 |
| 247 | rionero | 1 |
| 248 | rs1054190c | 1 |
| 249 | rs12700667 | 1 |
| 250 | rs1413239 | 1 |
| 251 | rs1799836 | 1 |
| 252 | rs2099489 | 1 |
| 253 | rs628031 | 1 |
| 254 | rs8179090 | 1 |
| 255 | rs818571 | 1 |
| 256 | rs989692 | 1 |
| 257 | s3l1-s3l6 | 1 |
| 258 | s4l1-s4l5 | 1 |
| 259 | self-experiment | 1 |
| 260 | ser124 | 1 |
| 261 | serdang | 1 |
| 262 | sglp | 1 |
| 263 | sixty-day-old | 1 |
| 264 | srna162 | 1 |
| 265 | sulfaquinoxaline | 1 |
| 266 | synchronically | 1 |
| 267 | synthetically-challenging | 1 |
| 268 | tetra-capped | 1 |
| 269 | thr854 | 1 |
| 270 | total-isolates | 1 |
| 271 | triglyceride-content | 1 |
| 272 | trisome-18 | 1 |
| 273 | uaa-pi | 1 |
| 274 | univentricle | 1 |
| 275 | uraturia | 1 |
| 276 | uretro-rectal | 1 |
| 277 | varing | 1 |
| 278 | vegetating | 1 |
| 279 | yupingfeng-san | 1 |
| 280 | yupingfengsan | 1 |
| 281 | ~1.4-fold | 1 |
| 282 | ~2.1-fold | 1 |
| 283 | ~2.4-fold | 1 |
| 284 | ~5.0-fold | 1 |
| 285 | ~5.1-fold | 1 |
| 286 | ~5.4-fold | 1 |
| 287 | ~5.8-fold | 1 |
| 288 | ~8.3-fold | 1 |
| 289 | £12,834 | 1 |
| 290 | ¥74 | 1 |
| 291 | α=0.919 | 1 |
| 292 | β-1,3-galnac | 1 |
| 293 | €1,564 | 1 |
| 294 | €10,942/qaly | 1 |
| 295 | €12,122/qaly | 1 |
| 296 | €1590 | 1 |
| 297 | €209 | 1 |
| 298 | €2256 | 1 |
| 299 | €297 | 1 |
| 1 | 'decline | 1 |
| 2 | 'probiotics | 1 |
| 3 | 'published | 2 |
| 4 | 'pumped | 1 |
| 5 | 'scenarios | 1 |
| 6 | +13/+17 | 1 |
| 7 | -5.9±6.5 | 1 |
| 8 | -8.1±6.4 | 1 |
| 9 | -patient | 1 |
| 10 | 0.04+/-3.94 | 1 |
| 11 | 0.10±0.01 | 2 |
| 12 | 0.23±0.04 | 1 |
| 13 | 0.28±0.01 | 1 |
| 14 | 0.4985 | 1 |
| 15 | 0.49±0.04 | 1 |
| 16 | 0.52±0.03 | 1 |
| 17 | 0.63/0.37 | 1 |
| 18 | 0.696+/-0.1 | 1 |
| 19 | 0.7406 | 1 |
| 20 | 0.745+/-0.03 | 1 |
| 21 | 0.82-fold | 1 |
| 22 | 0.83+/-3.88 | 1 |
| 23 | 0.86±0.51 | 1 |
| 24 | 0.87-0.87 | 1 |
| 25 | 09/gz/1081 | 1 |
| 26 | 1-15cm2 | 1 |
| 27 | 1.00-1.68 | 1 |
| 28 | 1.00/0.00 | 1 |
| 29 | 1.2-dicloroethane | 1 |
| 30 | 1.29-2.74 | 1 |
| 31 | 1.3db | 1 |
| 32 | 1.4-11.5 | 1 |
| 33 | 1.52-3.95 | 1 |
| 34 | 1.54-3.27 | 1 |
| 35 | 1.59+/-4.57 | 1 |
| 36 | 1.7±0.52 | 1 |
| 37 | 1.93±1.03 | 1 |
| 38 | 101.3±27.1 | 1 |
| 39 | 11,855 | 1 |
| 40 | 11cen-p14 | 1 |
| 41 | 12.57±2.05mg/dl | 1 |
| 42 | 12.7±7.9 | 1 |
| 43 | 12.7±9.5 | 1 |
| 44 | 134/qaly | 1 |
| 45 | 15.97±1.96mg/dl | 1 |
| 46 | 16±6°c | 1 |
| 47 | 18.0-30.4 | 1 |
| 48 | 182,546 | 1 |
| 49 | 2,777 | 1 |
| 50 | 2-dechloroethylifosfamide | 1 |
| 51 | 2-hydroxyisobutyrate | 1 |
| 52 | 2.18+/-0.76 | 1 |
| 53 | 2.4+/-0.3 | 1 |
| 54 | 2.9+/-1.3 | 1 |
| 55 | 20,290 | 1 |
| 56 | 20alpha-dihydroxypregn-4-en-3-one | 1 |
| 57 | 268/1075 | 1 |
| 58 | 283/1072 | 1 |
| 59 | 3.1+/-1.6 | 1 |
| 60 | 31-60° | 1 |
| 61 | 32,110 | 1 |
| 62 | 33/30 | 2 |
| 63 | 399gln | 2 |
| 64 | 4,4'-bipyridine-bridged | 1 |
| 65 | 4.1±1.2mm | 1 |
| 66 | 4.59±2.02 | 1 |
| 67 | 4.854 | 1 |
| 68 | 43.2mg | 1 |
| 69 | 4‒5 | 1 |
| 70 | 5.3±8.3weeks | 1 |
| 71 | 50.6-79.6 | 1 |
| 72 | 57°w | 1 |
| 73 | 61-90° | 1 |
| 74 | 64.4±27.5 | 1 |
| 75 | 7.1±13.9 | 1 |
| 76 | 7.98±0.41 | 1 |
| 77 | 77/111 | 1 |
| 78 | 7963 | 1 |
| 79 | 8-diones | 1 |
| 80 | 8-hydroxyclomipramine | 1 |
| 81 | 803a/a | 1 |
| 82 | 9.3/10 | 1 |
| 83 | 9890 | 1 |
| 84 | absent/present/abundant | 2 |
| 85 | abstracts/papers | 1 |
| 86 | alkynyltrifluoroborate | 1 |
| 87 | amman-jordan | 1 |
| 88 | analysis.evidence | 1 |
| 89 | ancylostomideos | 1 |
| 90 | anemia/hemorrhage | 1 |
| 91 | angled-tip | 1 |
| 92 | antagonists-is | 1 |
| 93 | anti-c5 | 1 |
| 94 | anti-ca-present | 1 |
| 95 | anti-ro52 | 1 |
| 96 | antibiotics/steroids/antihistamines | 1 |
| 97 | aphtha | 2 |
| 98 | apkcs | 2 |
| 99 | aq-27 | 1 |
| 100 | arg41 | 1 |
| 101 | asp863 | 1 |
| 102 | azospermia | 1 |
| 103 | bafetinib | 1 |
| 104 | basophilia | 1 |
| 105 | belingai | 1 |
| 106 | biphenols | 1 |
| 107 | bsrt | 1 |
| 108 | c.279-280insat | 1 |
| 109 | c262y/wt | 1 |
| 110 | c282y/c282y | 1 |
| 111 | c7/th1 | 1 |
| 112 | ca/p-containing | 1 |
| 113 | cardiomagnyl | 1 |
| 114 | cassrs | 1 |
| 115 | cdxzn1-xse-cdyzn1-ys | 1 |
| 116 | cephalothorax | 1 |
| 117 | ci:0.95-2.43 | 1 |
| 118 | ci:0.99-2.51 | 1 |
| 119 | cns-lupus | 1 |
| 120 | co-organized | 1 |
| 121 | coiled-coils | 1 |
| 122 | core-ceramic/veneer | 1 |
| 123 | cowork | 1 |
| 124 | cpd-photolyase | 1 |
| 125 | cross-contaminations | 1 |
| 126 | crystallising | 1 |
| 127 | culminating | 71 |
| 128 | custom-manufactured | 1 |
| 129 | cutting-in | 1 |
| 130 | decentre | 1 |
| 131 | dederivation | 1 |
| 132 | desisting | 1 |
| 133 | detaches | 2 |
| 134 | digitalis-especially | 1 |
| 135 | dimission | 1 |
| 136 | disbalances | 1 |
| 137 | disulphides | 1 |
| 138 | dppc/pg | 1 |
| 139 | drb1*09012 | 1 |
| 140 | driving/riding | 1 |
| 141 | e-prints | 1 |
| 142 | edads | 1 |
| 143 | egerton | 1 |
| 144 | enamels | 2 |
| 145 | end-labeled | 1 |
| 146 | endo-1,4-β-mannanases | 1 |
| 147 | endo-1→3-β-d-glucanase | 1 |
| 148 | epilepsy/seizures | 1 |
| 149 | erinia | 1 |
| 150 | eskornade | 1 |
| 151 | esspecially | 1 |
| 152 | estrangement | 1 |
| 153 | eventuating | 2 |
| 154 | f-e2 | 1 |
| 155 | f.c-e2 | 1 |
| 156 | feloten | 1 |
| 157 | ffar2 | 1 |
| 158 | folloed | 1 |
| 159 | framing-changing | 1 |
| 160 | g3pdhs | 1 |
| 161 | garnishes | 2 |
| 162 | gender-sensitised | 1 |
| 163 | genno-shoko | 1 |
| 164 | gse14407 | 2 |
| 165 | h63d/h63d | 1 |
| 166 | half-submerged | 2 |
| 167 | harris-shorr | 2 |
| 168 | heii-san | 1 |
| 169 | hexanedinitrile | 1 |
| 170 | hollow-structured | 1 |
| 171 | homovanillic-acid | 1 |
| 172 | hpa-3a | 1 |
| 173 | hsp84-transgene | 1 |
| 174 | hwangryun-hae-dok-decotion | 1 |
| 175 | hyper-connectivity | 3 |
| 176 | hyper-proportional | 1 |
| 177 | ido1-overexpression | 1 |
| 178 | ii-article | 1 |
| 179 | illegally-engaged | 1 |
| 180 | imipramin | 1 |
| 181 | immune-isolated | 1 |
| 182 | ischémiques | 1 |
| 183 | ita-oba | 1 |
| 184 | jugal | 1 |
| 185 | kaitha | 1 |
| 186 | khorasan-1037 | 1 |
| 187 | laminin-2 | 1 |
| 188 | landmarked | 1 |
| 189 | lazanda® | 1 |
| 190 | ld3 | 1 |
| 191 | leukoerythroblastosis | 1 |
| 192 | lexicalized | 3 |
| 193 | lignosulfonates | 1 |
| 194 | lipocrits | 1 |
| 195 | lipomeningocele | 1 |
| 196 | liqpiritin | 1 |
| 197 | log-uacr | 1 |
| 198 | m3a | 1 |
| 199 | m3b | 1 |
| 200 | macrodiscectomy | 2 |
| 201 | megusurino-ki | 1 |
| 202 | metallothione- | 1 |
| 203 | metxl50 | 1 |
| 204 | mg/al | 1 |
| 205 | miii | 1 |
| 206 | multicenter-trials | 1 |
| 207 | n'-disubstituted | 2 |
| 208 | nival | 1 |
| 209 | notch1-4 | 1 |
| 210 | npnz | 1 |
| 211 | o-bidentate | 2 |
| 212 | o-didesmethylvenlafaxine | 1 |
| 213 | obstruction/clogging | 1 |
| 214 | oprf/opri | 1 |
| 215 | orchid-epididymitis | 1 |
| 216 | p.l647f | 1 |
| 217 | painrelieving | 1 |
| 218 | particpation | 1 |
| 219 | pateint | 1 |
| 220 | pcrrflp | 1 |
| 221 | pdmpcisolated | 1 |
| 222 | peptidoleukotrienes | 1 |
| 223 | pg+cq | 1 |
| 224 | phloretin-3',5'-di-c-glucoside | 1 |
| 225 | pn1mi+ | 1 |
| 226 | pneumonia/ardss | 2 |
| 227 | pneuomothorax | 1 |
| 228 | polysaccharopeptide | 1 |
| 229 | polyuria/dehydration | 1 |
| 230 | preincubational | 1 |
| 231 | primases | 1 |
| 232 | progresssion | 1 |
| 233 | prostato-rectal | 1 |
| 234 | q-max | 1 |
| 235 | r=-0.032 | 1 |
| 236 | r=.87 | 1 |
| 237 | r=0.155 | 1 |
| 238 | rechu-to | 1 |
| 239 | redisplacement/nonunion | 2 |
| 240 | regin | 1 |
| 241 | remobilisation | 1 |
| 242 | resulting | 9,279 |
| 243 | rfs/os | 1 |
| 244 | rionero | 1 |
| 245 | rs1054190c | 1 |
| 246 | rs12700667 | 1 |
| 247 | rs1413239 | 1 |
| 248 | rs1799836 | 1 |
| 249 | rs2099489 | 1 |
| 250 | rs3828610 | 2 |
| 251 | rs628031 | 1 |
| 252 | rs8179090 | 1 |
| 253 | rs818571 | 1 |
| 254 | rs989692 | 1 |
| 255 | s3l1-s3l6 | 1 |
| 256 | s4l1-s4l5 | 1 |
| 257 | self-experiment | 1 |
| 258 | ser124 | 1 |
| 259 | serdang | 1 |
| 260 | sglp | 1 |
| 261 | sixty-day-old | 1 |
| 262 | src-3/amplified | 2 |
| 263 | srna162 | 1 |
| 264 | sulfaquinoxaline | 1 |
| 265 | synchronically | 1 |
| 266 | synthetically-challenging | 1 |
| 267 | tetra-capped | 1 |
| 268 | thr854 | 1 |
| 269 | total-isolates | 1 |
| 270 | triglyceride-content | 1 |
| 271 | trisome-18 | 1 |
| 272 | uaa-pi | 1 |
| 273 | univentricle | 1 |
| 274 | uraturia | 1 |
| 275 | uretro-rectal | 1 |
| 276 | varing | 1 |
| 277 | vegetating | 1 |
| 278 | yupingfeng-san | 1 |
| 279 | yupingfengsan | 1 |
| 280 | ~1.4-fold | 1 |
| 281 | ~2.1-fold | 1 |
| 282 | ~2.4-fold | 1 |
| 283 | ~5.0-fold | 1 |
| 284 | ~5.1-fold | 1 |
| 285 | ~5.4-fold | 1 |
| 286 | ~5.8-fold | 1 |
| 287 | ~8.3-fold | 1 |
| 288 | £12,834 | 1 |
| 289 | ¥74 | 1 |
| 290 | α=0.919 | 1 |
| 291 | β-1,3-galnac | 1 |
| 292 | ω-diols | 3 |
| 293 | €1,564 | 1 |
| 294 | €10,942/qaly | 1 |
| 295 | €12,122/qaly | 1 |
| 296 | €1590 | 1 |
| 297 | €209 | 1 |
| 298 | €2256 | 1 |
| 299 | €297 | 1 |
| 1 | pn1mi+ | 1 |
| 2 | metallothione- | 1 |
| 3 | 1.00/0.00 | 1 |
| 4 | 9.3/10 | 1 |
| 5 | 32,110 | 1 |
| 6 | rs3828610 | 2 |
| 7 | 33/30 | 2 |
| 8 | metxl50 | 1 |
| 9 | rs8179090 | 1 |
| 10 | 20,290 | 1 |
| 11 | €1590 | 1 |
| 12 | 9890 | 1 |
| 13 | 0.696+/-0.1 | 1 |
| 14 | 101.3±27.1 | 1 |
| 15 | 0.10±0.01 | 2 |
| 16 | 0.28±0.01 | 1 |
| 17 | 77/111 | 1 |
| 18 | rs628031 | 1 |
| 19 | 7.98±0.41 | 1 |
| 20 | arg41 | 1 |
| 21 | 0.86±0.51 | 1 |
| 22 | ci:0.99-2.51 | 1 |
| 23 | rs818571 | 1 |
| 24 | 09/gz/1081 | 1 |
| 25 | c7/th1 | 1 |
| 26 | laminin-2 | 1 |
| 27 | 4.59±2.02 | 1 |
| 28 | drb1*09012 | 1 |
| 29 | r=-0.032 | 1 |
| 30 | 1.7±0.52 | 1 |
| 31 | anti-ro52 | 1 |
| 32 | srna162 | 1 |
| 33 | 283/1072 | 1 |
| 34 | rs989692 | 1 |
| 35 | f.c-e2 | 1 |
| 36 | f-e2 | 1 |
| 37 | 1-15cm2 | 1 |
| 38 | ffar2 | 1 |
| 39 | 2.4+/-0.3 | 1 |
| 40 | 2.9+/-1.3 | 1 |
| 41 | 0.745+/-0.03 | 1 |
| 42 | 0.52±0.03 | 1 |
| 43 | 1.93±1.03 | 1 |
| 44 | ci:0.95-2.43 | 1 |
| 45 | asp863 | 1 |
| 46 | 7963 | 1 |
| 47 | ld3 | 1 |
| 48 | notch1-4 | 1 |
| 49 | 18.0-30.4 | 1 |
| 50 | -8.1±6.4 | 1 |
| 51 | 0.23±0.04 | 1 |
| 52 | 0.49±0.04 | 1 |
| 53 | 11cen-p14 | 1 |
| 54 | ser124 | 1 |
| 55 | £12,834 | 1 |
| 56 | 4.854 | 1 |
| 57 | thr854 | 1 |
| 58 | €1,564 | 1 |
| 59 | 1.29-2.74 | 1 |
| 60 | ¥74 | 1 |
| 61 | 0.04+/-3.94 | 1 |
| 62 | 1.4-11.5 | 1 |
| 63 | -5.9±6.5 | 1 |
| 64 | 64.4±27.5 | 1 |
| 65 | 12.7±9.5 | 1 |
| 66 | r=0.155 | 1 |
| 67 | 11,855 | 1 |
| 68 | 268/1075 | 1 |
| 69 | 0.4985 | 1 |
| 70 | 1.52-3.95 | 1 |
| 71 | anti-c5 | 1 |
| 72 | s4l1-s4l5 | 1 |
| 73 | 4‒5 | 1 |
| 74 | 3.1+/-1.6 | 1 |
| 75 | 50.6-79.6 | 1 |
| 76 | 0.7406 | 1 |
| 77 | rs1799836 | 1 |
| 78 | 182,546 | 1 |
| 79 | €2256 | 1 |
| 80 | 2.18+/-0.76 | 1 |
| 81 | s3l1-s3l6 | 1 |
| 82 | gse14407 | 2 |
| 83 | +13/+17 | 1 |
| 84 | aq-27 | 1 |
| 85 | 1.54-3.27 | 1 |
| 86 | 0.63/0.37 | 1 |
| 87 | khorasan-1037 | 1 |
| 88 | 1.59+/-4.57 | 1 |
| 89 | rs12700667 | 1 |
| 90 | 2,777 | 1 |
| 91 | 0.87-0.87 | 1 |
| 92 | r=.87 | 1 |
| 93 | €297 | 1 |
| 94 | trisome-18 | 1 |
| 95 | 1.00-1.68 | 1 |
| 96 | 0.83+/-3.88 | 1 |
| 97 | 7.1±13.9 | 1 |
| 98 | 12.7±7.9 | 1 |
| 99 | €209 | 1 |
| 100 | α=0.919 | 1 |
| 101 | rs1413239 | 1 |
| 102 | rs2099489 | 1 |
| 103 | 803a/a | 1 |
| 104 | hpa-3a | 1 |
| 105 | m3a | 1 |
| 106 | ita-oba | 1 |
| 107 | aphtha | 2 |
| 108 | kaitha | 1 |
| 109 | basophilia | 1 |
| 110 | azospermia | 1 |
| 111 | erinia | 1 |
| 112 | uraturia | 1 |
| 113 | m3b | 1 |
| 114 | 1.3db | 1 |
| 115 | bafetinib | 1 |
| 116 | rs1054190c | 1 |
| 117 | β-1,3-galnac | 1 |
| 118 | 16±6°c | 1 |
| 119 | h63d/h63d | 1 |
| 120 | illegally-engaged | 1 |
| 121 | 4,4'-bipyridine-bridged | 1 |
| 122 | half-submerged | 2 |
| 123 | 'published | 2 |
| 124 | src-3/amplified | 2 |
| 125 | landmarked | 1 |
| 126 | end-labeled | 1 |
| 127 | folloed | 1 |
| 128 | 'pumped | 1 |
| 129 | tetra-capped | 1 |
| 130 | custom-manufactured | 1 |
| 131 | hollow-structured | 1 |
| 132 | gender-sensitised | 1 |
| 133 | immune-isolated | 1 |
| 134 | pdmpcisolated | 1 |
| 135 | n'-disubstituted | 2 |
| 136 | lexicalized | 3 |
| 137 | co-organized | 1 |
| 138 | homovanillic-acid | 1 |
| 139 | sixty-day-old | 1 |
| 140 | ~5.0-fold | 1 |
| 141 | ~2.1-fold | 1 |
| 142 | ~5.1-fold | 1 |
| 143 | 0.82-fold | 1 |
| 144 | ~8.3-fold | 1 |
| 145 | ~1.4-fold | 1 |
| 146 | ~2.4-fold | 1 |
| 147 | ~5.4-fold | 1 |
| 148 | ~5.8-fold | 1 |
| 149 | analysis.evidence | 1 |
| 150 | eskornade | 1 |
| 151 | 2-dechloroethylifosfamide | 1 |
| 152 | phloretin-3',5'-di-c-glucoside | 1 |
| 153 | polysaccharopeptide | 1 |
| 154 | anemia/hemorrhage | 1 |
| 155 | univentricle | 1 |
| 156 | ii-article | 1 |
| 157 | lipomeningocele | 1 |
| 158 | hexanedinitrile | 1 |
| 159 | 1.2-dicloroethane | 1 |
| 160 | hsp84-transgene | 1 |
| 161 | sulfaquinoxaline | 1 |
| 162 | 'decline | 1 |
| 163 | 8-hydroxyclomipramine | 1 |
| 164 | o-didesmethylvenlafaxine | 1 |
| 165 | 20alpha-dihydroxypregn-4-en-3-one | 1 |
| 166 | decentre | 1 |
| 167 | endo-1→3-β-d-glucanase | 1 |
| 168 | cpd-photolyase | 1 |
| 169 | alkynyltrifluoroborate | 1 |
| 170 | 2-hydroxyisobutyrate | 1 |
| 171 | o-bidentate | 2 |
| 172 | p.l647f | 1 |
| 173 | 43.2mg | 1 |
| 174 | serdang | 1 |
| 175 | driving/riding | 1 |
| 176 | obstruction/clogging | 1 |
| 177 | framing-changing | 1 |
| 178 | synthetically-challenging | 1 |
| 179 | ca/p-containing | 1 |
| 180 | varing | 1 |
| 181 | crystallising | 1 |
| 182 | culminating | 71 |
| 183 | vegetating | 1 |
| 184 | eventuating | 2 |
| 185 | resulting | 9,279 |
| 186 | desisting | 1 |
| 187 | painrelieving | 1 |
| 188 | dppc/pg | 1 |
| 189 | belingai | 1 |
| 190 | miii | 1 |
| 191 | megusurino-ki | 1 |
| 192 | uaa-pi | 1 |
| 193 | oprf/opri | 1 |
| 194 | cowork | 1 |
| 195 | mg/al | 1 |
| 196 | jugal | 1 |
| 197 | preincubational | 1 |
| 198 | hyper-proportional | 1 |
| 199 | uretro-rectal | 1 |
| 200 | prostato-rectal | 1 |
| 201 | nival | 1 |
| 202 | 12.57±2.05mg/dl | 1 |
| 203 | 15.97±1.96mg/dl | 1 |
| 204 | cardiomagnyl | 1 |
| 205 | 4.1±1.2mm | 1 |
| 206 | amman-jordan | 1 |
| 207 | yupingfeng-san | 1 |
| 208 | heii-san | 1 |
| 209 | yupingfengsan | 1 |
| 210 | feloten | 1 |
| 211 | cutting-in | 1 |
| 212 | regin | 1 |
| 213 | imipramin | 1 |
| 214 | liqpiritin | 1 |
| 215 | 399gln | 2 |
| 216 | redisplacement/nonunion | 2 |
| 217 | ido1-overexpression | 1 |
| 218 | dimission | 1 |
| 219 | progresssion | 1 |
| 220 | particpation | 1 |
| 221 | polyuria/dehydration | 1 |
| 222 | remobilisation | 1 |
| 223 | dederivation | 1 |
| 224 | hwangryun-hae-dok-decotion | 1 |
| 225 | egerton | 1 |
| 226 | genno-shoko | 1 |
| 227 | rionero | 1 |
| 228 | rechu-to | 1 |
| 229 | angled-tip | 1 |
| 230 | pcrrflp | 1 |
| 231 | sglp | 1 |
| 232 | pg+cq | 1 |
| 233 | log-uacr | 1 |
| 234 | core-ceramic/veneer | 1 |
| 235 | harris-shorr | 2 |
| 236 | 'probiotics | 1 |
| 237 | apkcs | 2 |
| 238 | edads | 1 |
| 239 | disbalances | 1 |
| 240 | disulphides | 1 |
| 241 | detaches | 2 |
| 242 | garnishes | 2 |
| 243 | peptidoleukotrienes | 1 |
| 244 | antibiotics/steroids/antihistamines | 1 |
| 245 | 8-diones | 1 |
| 246 | epilepsy/seizures | 1 |
| 247 | primases | 1 |
| 248 | endo-1,4-β-mannanases | 1 |
| 249 | total-isolates | 1 |
| 250 | lignosulfonates | 1 |
| 251 | ischémiques | 1 |
| 252 | g3pdhs | 1 |
| 253 | antagonists-is | 1 |
| 254 | leukoerythroblastosis | 1 |
| 255 | orchid-epididymitis | 1 |
| 256 | 5.3±8.3weeks | 1 |
| 257 | multicenter-trials | 1 |
| 258 | enamels | 2 |
| 259 | coiled-coils | 1 |
| 260 | ω-diols | 3 |
| 261 | biphenols | 1 |
| 262 | cross-contaminations | 1 |
| 263 | rfs/os | 1 |
| 264 | ancylostomideos | 1 |
| 265 | 'scenarios | 1 |
| 266 | abstracts/papers | 1 |
| 267 | cassrs | 1 |
| 268 | pneumonia/ardss | 2 |
| 269 | lipocrits | 1 |
| 270 | e-prints | 1 |
| 271 | cns-lupus | 1 |
| 272 | cdxzn1-xse-cdyzn1-ys | 1 |
| 273 | c.279-280insat | 1 |
| 274 | absent/present/abundant | 2 |
| 275 | -patient | 1 |
| 276 | estrangement | 1 |
| 277 | self-experiment | 1 |
| 278 | anti-ca-present | 1 |
| 279 | triglyceride-content | 1 |
| 280 | pateint | 1 |
| 281 | bsrt | 1 |
| 282 | c262y/wt | 1 |
| 283 | 57°w | 1 |
| 284 | q-max | 1 |
| 285 | cephalothorax | 1 |
| 286 | pneuomothorax | 1 |
| 287 | c282y/c282y | 1 |
| 288 | €12,122/qaly | 1 |
| 289 | €10,942/qaly | 1 |
| 290 | 134/qaly | 1 |
| 291 | synchronically | 1 |
| 292 | digitalis-especially | 1 |
| 293 | esspecially | 1 |
| 294 | macrodiscectomy | 2 |
| 295 | hyper-connectivity | 3 |
| 296 | npnz | 1 |
| 297 | lazanda® | 1 |
| 298 | 31-60° | 1 |
| 299 | 61-90° | 1 |